| 2026-08-06 | 8-K | 10.1 | Second Amended and Restated Sales Agreement, dated August 6, 2026, by and among the Company, Leerink Partners LLC and Cantor Fitzgerald & Co. |
|---|
| 2025-11-06 | 10-Q | 10.1 | Employment Agreement, effective as of July 28, 2025, by and between the Registrant and Roland Kolbeck. |
|---|
| 2025-06-05 | 8-K | 10.3 | Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement used in connection with the Aclaris Therapeutics, Inc. 2025 Equity Incentive Plan. |
|---|
| 2025-06-05 | 8-K | 10.2 | Form of Stock Option Grant Notice and Option Agreement used in connection with the Aclaris Therapeutics, Inc. 2025 Equity Incentive Plan. |
|---|
| 2025-06-05 | 8-K | 10.1 | Aclaris Therapeutics, Inc. 2025 Equity Incentive Plan. |
|---|
| 2025-05-08 | 10-Q | 10.4 | Tenth Amended and Restated Non-Employee Director Compensation Policy. |
|---|
| 2025-05-08 | 10-Q | 10.3 | Employment Agreement, dated as of April 28, 2025, by and between the Registrant and Jesse Hall. |
|---|
| 2025-02-27 | 10-K | 10.28 | Form of Common Stock Purchase Warrant Agreement issued on November 18, 2024. |
|---|
| 2025-02-27 | 10-K | 10.27 | Collaboration Agreement, dated as of November 18, 2024, by and among the Registrant, Biosion, Inc. and Chia Tai Tianqing Pharmaceutical Group, Co., Ltd. |
|---|
| 2025-02-27 | 10-K | 10.26 | Exclusive License Agreement, dated as of November 18, 2024, by and between the Registrant and Biosion, Inc. |
|---|
| 2025-02-27 | 10-K | 10.24 | Amended and Restated Sales Agreement, dated February 27, 2025, by and among the Registrant, Leerink Partners LLC and Cantor Fitzgerald & Co. |
|---|
| 2025-02-27 | 10-K | 10.21 | Employment Agreement, dated as of February 26, 2025, by and between the Registrant and Neal Walker. |
|---|
| 2024-11-18 | 8-K | 10.6 | Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement used in connection with the Aclaris Therapeutics, Inc. 2024 Inducement Plan. |
|---|
| 2024-11-18 | 8-K | 10.5 | Form of Stock Option Grant Notice and Stock Option Agreement used in connection with the Aclaris Therapeutics, Inc. 2024 Inducement Plan. |
|---|
| 2024-11-18 | 8-K | 10.4 | Aclaris Therapeutics, Inc. 2024 Inducement Plan. |
|---|
| 2024-11-18 | 8-K | 10.3 | Employment Agreement, dated as of November 18, 2024, by and between the Company and Hugh Davis. |
|---|
| 2024-11-18 | 8-K | 10.2 | Form of Registration Rights Agreement, dated November 18, 2024, by and between the Company and the investors named therein. |
|---|
| 2024-11-18 | 8-K | 10.1 | Form of Securities Purchase Agreement, dated November 18, 2024, by and between the Company and the investors named therein. |
|---|
| 2024-08-07 | 10-Q | 10.1 | Royalty Purchase Agreement, effective as of July 16, 2024, by and between the Registrant and OCM IP Healthcare Portfolio LP. |
|---|
| 2024-02-27 | 10-K | 10.22 | Letter Agreement, dated as of January 31, 2024, by and between the Registrant and Neal Walker. |
|---|
| 2024-02-27 | 10-K | 10.18 | Separation Agreement, Waiver, and Release, dated as of February 4, 2024, by and between the Registrant and Douglas Manion. |
|---|
| 2024-02-27 | 10-K | 10.15 | Second Amended and Restated Employment Agreement, effective as of February 1, 2024, by and between the Registrant and Joseph Monahan. |
|---|
| 2023-06-12 | 8-K | 10.1 | Amended and Restated Employment Agreement, effective as of July 1, 2023, by and between the Company and Joseph Monahan. |
|---|
| 2023-06-01 | 8-K | 10.1 | Office Lease, dated May 26, 2023, by and between the Company and CBCC – Lee Road Acquisitions, LLC. |
|---|
| 2023-05-08 | 10-Q | 10.4 | Ninth Amended and Restated Non-Employee Director Compensation Policy. |
|---|
| 2023-03-27 | 8-K | 10.1 | Amendment No. 1 to Consulting Services Agreement, dated as of March 23, 2023, by and between the Company and Frank Ruffo. |
|---|
| 2023-02-23 | 10-K | 10.24 | Employment Agreement, dated as of January 1, 2023, by and between the Registrant and Kevin Balthaser. |
|---|
| 2023-02-23 | 10-K | 10.23 | Amended and Restated Employment Agreement, dated as of January 1, 2023, by and between the Registrant and Douglas Manion. |
|---|
| 2023-02-23 | 10-K | 10.19 | Consulting Agreement, dated as of January 1, 2023, by and between the Registrant and Frank Ruffo. |
|---|
| 2023-02-23 | 10-K | 10.18 | Separation Agreement and General Release, dated as of December 9, 2022, by and between the Registrant and Frank Ruffo. |
|---|
| 2023-02-23 | 10-K | 10.16 | Letter Agreement, dated as of November 22, 2022, by and between the Registrant and Neal Walker. |
|---|
| 2023-02-23 | 10-K | 10.12 | Eighth Amended and Restated Non-Employee Director Compensation Policy. |
|---|
| 2023-02-23 | 8-K | 10.1 | Sales Agreement, dated February 23, 2023, by and among Aclaris Therapeutics, Inc., SVB Securities LLC and Cantor Fitzgerald & Co. |
|---|
| 2022-08-03 | 10-Q | 10.1 | Employment Agreement, dated as of June 27, 2022, by and between the Registrant and Gail Cawkwell. |
|---|
| 2022-08-01 | 8-K | 10.1 | Employment Agreement, dated as of August 1, 2022, by and between the Company and Douglas Manion. |
|---|
| 2022-02-24 | 10-K | 10.23 | Seventh Amended and Restated Non-Employee Director Compensation Policy. |
|---|
| 2022-02-24 | 10-K | 10.18 | Severance Agreement and General Release, dated as of January 7, 2022, by and between the Registrant and David Gordon. |
|---|
| 2022-02-24 | 10-K | 10.17 | Severance Agreement and General Release, dated as of November 1, 2021, by and between the Registrant and Kamil Ali-Jackson. |
|---|
| 2022-02-24 | 10-K | 10.16 | Employment Agreement, dated as of January 31, 2022, by and between the Registrant and James Loerop. |
|---|
| 2022-02-24 | 10-K | 10.15 | Employment Agreement, dated as of January 12, 2022, by and between the Registrant and Joseph Monahan. |
|---|
| 2022-02-24 | 10-K | 10.12 | Sixth Amended and Restated Non-Employee Director Compensation Policy. |
|---|
| 2022-01-14 | 8-K | 10.2 | Amended and Restated Employment Agreement, dated as of January 12, 2022, by and between the Company and Frank Ruffo. |
|---|
| 2022-01-14 | 8-K | 10.1 | Amended and Restated Employment Agreement, dated as of January 12, 2022, by and between the Company and Neal Walker. |
|---|
| 2021-08-05 | 10-Q | 10.1 | Fifth Amended and Restated Non-Employee Director Compensation Policy. |
|---|
| 2021-05-20 | 8-K | 10.1 | Sales Agreement, dated May 20, 2021, by and among Aclaris Therapeutics, Inc., SVB Leerink LLC and Cantor Fitzgerald & Co. |
|---|
| 2021-02-25 | 10-K | 10.16 | Change in Control Severance Benefit Plan, effective January 1, 2017, as amended by First Amendment to Change in Control Severance Benefit Plan, effective October 2, 2019. |
|---|
| 2021-02-25 | 10-K | 10.12 | Fourth Amended and Restated Non-Employee Director Compensation Policy. |
|---|
| 2020-08-13 | 8-K | 10.2 | Registration Rights Agreement, dated as of August 13, 2020, by and between the Company and Lincoln Park. |
|---|
| 2020-08-13 | 8-K | 10.1 | Purchase Agreement, dated as of August 13, 2020, by and between the Company and Lincoln Park. |
|---|
| 2020-08-07 | 10-Q | 10.2 | First Amendment to Clinical and Commercial Supply Agreement, dated as of June 12, 2020, by and between the Registrant and PeroxyChem LLC. |
|---|
| 2020-05-07 | 10-Q | 10.5 | Second Amendment to Sublease, dated as of April 29, 2020, by and between the Registrant and Auxilium Pharmaceuticals, LLC. |
|---|
| 2020-03-31 | 8-K | 10.2 | Warrant to Purchase Stock, issued to Silicon Valley Bank, dated as of March 30, 2020. |
|---|
| 2020-03-31 | 8-K | 10.1 | Loan and Security Agreement, by and among the Company, Confluence Discovery Technologies, Inc. and Silicon Valley Bank, dated as of March 30, 2020. |
|---|
| 2020-03-13 | 8-K | 10.1 | Open Market Sale Agreement, dated March 13, 2020, by and between Aclaris Therapeutics, Inc. and Jefferies LLC. |
|---|
| 2020-02-25 | 10-K | 10.20 | Employment Agreement with Frank Ruffo, dated as of September 17, 2015. |
|---|
| 2020-02-25 | 10-K | 10.15 | Third Amended and Restated Non-Employee Director Compensation Policy. |
|---|
| 2020-02-25 | 10-K | 10.14 | Second Amended and Restated Non-Employee Director Compensation Policy. |
|---|
| 2019-10-17 | 8-K | 10.1 | First Amendment to License and Collaboration Agreement, by and between the Company and Rigel Pharmaceuticals, Inc. dated as of October 15, 2019. |
|---|
| 2019-03-18 | 10-K | 10.31 | Loan and Security Agreement, dated as of October 15, 2018, by and among Oxford Finance LLC, the lenders party thereto, the Registrant, Confluence Discovery Technologies, Inc. and Aclaris Life Sciences, Inc., as amended by First Amendment to Loan and Security Agreement, dated as of January 28, 2019. |
|---|
| 2019-03-18 | 10-K | 10.27 | First Amendment to Sublease, dated as of December 13, 2017, by and between the Registrant and Auxilium Pharmaceuticals, LLC. |
|---|
| 2019-03-18 | 10-K | 10.15 | Amended & Restated Non-Employee Director Compensation Policy. |
|---|
| 2019-03-18 | 10-K | 10.12 | Form of Performance Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement used in connection with the 2015 Equity Incentive Plan. |
|---|
| 2019-03-18 | 10-K | 10.11 | Form of Performance Stock Option Grant Notice and Stock Option Agreement used in connection with the 2015 Equity Incentive Plan. |
|---|
| 2018-12-03 | 8-K | 10.1 | Exclusive Patent License Agreement, by and between the Company and Allergan, Inc., dated as of November 30, 2018. |
|---|
| 2018-08-03 | 10-Q | 10.2 | First Amendment to License Agreement, by and between The Trustees of Columbia University in the City of New York and the Registrant, dated as of June 27, 2018. |
|---|
| 2018-08-03 | 10-Q | 10.1 | Distribution Agreement, by and between the Registrant and McKesson Specialty Care Distribution Corporation, dated as of October 13, 2017, as amended by Amendment No. 1, dated as of March 6, 2018. |
|---|
| 2018-05-08 | 10-Q | 10.1 | Commercial Supply Manufacturing Services Agreement, by and between the Registrant and James Alexander Corporation, dated as of January 24, 2018. |
|---|
| 2017-11-07 | 10-Q | 10.1 | Fifth Amendment to Amended and Restated Sublease, by and between the Registrant and NST Consulting, LLC, dated as of July 17, 2017. |
|---|
| 2017-11-06 | 8-K | 10.1 | Sublease, dated November 2, 2017, by and between the Company and Auxilium Pharmaceuticals, LLC. |
|---|
| 2017-08-08 | 10-Q | 10.1 | Seventh Amendment to Services Agreement between the Registrant and NST Consulting, LLC, dated as of May 11, 2017. |
|---|
| 2017-08-01 | 8-K | 10.3 | (2017 Inducement Plan) |
|---|
| 2017-08-01 | 8-K | 10.2 | 2017 Inducement Plan |
|---|
| 2017-08-01 | 8-K | 10.1 | Lindenwood Drive, Suite |
|---|
| 2017-05-09 | 10-Q | 10.1 | Employment Agreement with Kamil Ali-Jackson, dated as of September 17, 2015. |
|---|
| 2017-03-15 | 10-K | 10.25 | Sixth Amendment to Services Agreement by and between the Registrant and NST Consulting, LLC, dated as of December 21, 2016. |
|---|
| 2017-03-15 | 10-K | 10.24 | Fourth Amendment to Amended and Restated Sublease, by and between the Registrant and NST Consulting, LLC, dated as of October 24, 2016. |
|---|
| 2016-11-02 | 8-K | 10.1 | Common Stock Sales Agreement, dated November 2, 2016, by and between Aclaris Therapeutics, Inc. and Cowen and Company, LLC. |
|---|
| 2016-06-02 | 8-K | 10.2 | Registration Rights Agreement, dated May 27, 2016, by and between Aclaris Therapeutics, Inc. and the investors named therein. |
|---|
| 2016-06-02 | 8-K | 10.1 | Securities Purchase Agreement, dated May 27, 2016, by and between Aclaris Therapeutics, Inc. and the investors named therein. |
|---|
| 2016-05-11 | 10-Q | 10.5 | Third Amendment to Amended and Restated Sublease, by and between the Registrant and NST Consulting, LLC, dated as of February 8, 2016 |
|---|
| 2016-05-11 | 10-Q | 10.4 | Fifth Amendment to Services Agreement by and between the Registrant and NST Consulting, LLC, dated as of January 8, 2016. |
|---|
| 2016-05-11 | 10-Q | 10.3 | Fourth Amendment to Services Agreement by and between the Registrant and NST Consulting, LLC, dated as of January 8, 2016. |
|---|
| 2016-05-11 | 10-Q | 10.2 | Third Amendment to Services Agreement by and between the Registrant and NST Consulting, LLC, dated as of November 24, 2015. |
|---|
| 2016-05-11 | 10-Q | 10.1 | Exclusive License Agreement, by and between The Trustees of Columbia University in the City of New York and Vixen Pharmaceuticals, Inc., dated as of December 31, 2015. |
|---|
| 2015-11-18 | 10-Q | 10.3 | Employment Agreement, by and between the Registrant and Christopher Powala, dated as of September 17, 2015. |
|---|
| 2015-11-18 | 10-Q | 10.2 | Employment Agreement, by and between the Registrant and Stuart Shanler, dated as of October 4, 2015. |
|---|
| 2015-11-18 | 10-Q | 10.1 | Amended and Restated Employment Agreement, by and between the Registrant and Neal Walker, dated as of October 5, 2015. |
|---|